

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7374879

| | | |
|---|--|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | |
| NATURE OF CONVEYANCE: | ASSIGNMENT | |
| CONVEYING PARTY DATA | | |
| | Name | Execution Date |
| | TINGYING ZHU | 10/19/2020 |
| RECEIVING PARTY DATA | | |
| Name: | CHINA INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. | |
| Street Address: | 4218 JINKE ROAD, PUDONG NEW AREA | |
| City: | SHANGHAI | |
| State/Country: | CHINA | |
| Postal Code: | 201203 | |
| PROPERTY NUMBERS Total: 1 | | |
| | Property Type | Number |
| | Application Number: | 17076126 |
| CORRESPONDENCE DATA | | |
| Fax Number: | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | |
| Email: | kristina.fay@novartis.com, pip_inbox.phchbs@novartis.com | |
| Correspondent Name: | KRISTINA FAY | |
| Address Line 1: | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | |
| Address Line 2: | 700 MAIN STREET | |
| Address Line 4: | CAMBRIDGE, MASSACHUSETTS 02139 | |
| ATTORNEY DOCKET NUMBER: | PAT058712-US-NP | |
| NAME OF SUBMITTER: | KRISTINA FAY | |
| SIGNATURE: | /Kristina Fay/ | |
| DATE SIGNED: | 06/09/2022 | |
| Total Attachments: 4 | | |
| source=PAT058712-WO-PCT_ASSIGN_ZHU_CNIBR#page1.tif | | |
| source=PAT058712-WO-PCT_ASSIGN_ZHU_CNIBR#page2.tif | | |
| source=PAT058712-WO-PCT_ASSIGN_ZHU_CNIBR#page3.tif | | |
| source=PAT058712-WO-PCT_ASSIGN_ZHU_CNIBR#page4.tif | | |

ASSIGNMENT

This Assignment Agreement is entered into by and between:

| | | |
|--------------|------------------|---|
| Tingying Zhu | citizen of China | Room 803 building 8, Lane 500, Lansong Road Pudong Shanghai, 201203 CHINA |
|--------------|------------------|---|

(hereinafter "Inventor(s)"),

and CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD.,
4218 Jinke Road, Pudong New Area, Shanghai, People's Republic of China, a company
organized under the laws of People's Republic of China.

For good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law
and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer
of employee inventions in my/our country of employment, CHINA NOVARTIS INSTITUTES
FOR BIOMEDICAL RESEARCH CO., LTD., is the true and lawful owner of all right, title
and interest in all inventions, discoveries, patents/utility models, applications, and rights
described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any
ownership right, title or interest in any of the items described herein (which I/We do not believe
to be the case and make no claim in or to), for good and valuable consideration, the receipt and
adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and
transfer to CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO.,
LTD., and its successors, assigns and legal representatives (hereinafter referred to collectively as
the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-
provisional patent, utility model, or other application(s) entitled

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

and filed in PCT Application on 20.09.2020 and accorded
Application Number PCT/CN2020/12214;

(2) the application(s) identified in paragraph (1), and all applications claiming priority
from such application(s), directly or indirectly, including all national stages of any international
patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or
discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 19 day of Oct, 2020

Tingying Zhu
Tingying Zhu

Witness: Joyce Zhao
Printed Name: Joyce Zhao
City, State and Country: Shanghai, China

Witness: Fang Wang
Printed Name: Fang Wang
City, State and Country: Shanghai, China

PAT058712-WO-PCT

Executed this 21 day of Oct, 20

CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD.

BY

Printed Name:

Authorized Signatory

Anfan Wu

Witness:

Lily Yu

Printed Name:

City, State and Country: SHANGHAI, CHINA

Witness:

Bohan Hu

Printed Name: Bohan Hu

City, State and Country: SHANGHAI, CHINA